RT Journal Article
SR Electronic
T1 Transcriptomics of acute DENV-specific CD8+ T cells does not support qualitative differences as drivers of disease severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.01.21262833
DO 10.1101/2021.09.01.21262833
A1 Grifoni, Alba
A1 Voic, Hannah
A1 Mateus, Jose
A1 Fung, Kai Mei Yan
A1 Wang, Alice
A1 Seumois, Grégory
A1 De Silva, Aruna D.
A1 Tennekon, Rashika
A1 Premawansa, Sunil
A1 Premawansa, Gayani
A1 Tippalgama, Rashmi
A1 Wijewickrama, Ananda
A1 Chawla, Ashu
A1 Greenbaum, Jason
A1 Peters, Bjoern
A1 Pandagrundan, Vijayanand
A1 Weiskopf, Daniela
A1 Sette, Alessandro
YR 2021
UL http://medrxiv.org/content/early/2021/09/03/2021.09.01.21262833.abstract
AB While several lines of evidence suggest a protective role of T cells against disease associated with Dengue virus (DENV) infection, their potential contribution to immunopathology in the acute phase of DENV infection remains controversial, and it has been hypothesized that the more severe form of the disease (dengue hemorrhagic fever, DHF) is associated with altered T cell responses. To address this question, we determined the transcriptomic profiles of DENV-specific CD8+T cells in a cohort of 40 hospitalized DENV donors with either a milder form of the disease (dengue fever, DF) or a more severe disease form (dengue hemorrhagic fever, DHF). We found multiple transcriptomic signatures, one associated with DENV-specific Interferon-gamma responding cells, and two other gene signatures, one specifically associated with the acute phase, and the other with the early convalescent phase. Additionally, we found no differences in quantity and quality of DENV-specific CD8+T cells based on disease severity. Taken together with previous findings that did not detect altered DENV-specific CD4 T cell responses, the current analysis argues against alteration in DENV-specific T cell responses as being a correlate of immunopathology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number U19 AI118626 to A.S and B.P. In addition, the HiSeq 2500 was acquired through the NIH Shared Instrumentation Grant (SIG) Program (S10): S10OD016262. We would like to thank LJI Flow cytometry Core for their support. The FACSAria II Cell Sorter was acquired through the Shared Instrumentation Grant (SIG) Program (S10) S10 RR027366.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review boards of both the La Jolla Institute for Immunology and the Medical Faculty, University of Colombo (serving as the NIH-approved Institutional Review Board for Genetech and Kotelawala Defence University), approved all protocols (VD-064, VD-085, EC-15-095) described in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe RNA-Seq data were deposited in the NCBI Gene Expression Omnibus (GEO) database under the accession code GSE174482